The Priority Review

Tag

SHINE-2

1 story

Stories

  1. Clinical trials

    Lilly's Omvoh meets primary endpoint of clinical remission in pediatric ulcerative colitis

    In the single-arm, open-label Phase 3 SHINE-2 study, 81% of 63 pediatric patients achieved clinical response at Week 12 and 50% of responders were in clinical remission at Week 52, meeting the study's primary endpoint. The safety profile through Week 52 was consistent with that seen in adults, with no new safety signals reported.